GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genix Pharmaceuticals Corp (TSXV:GENX) » Definitions » Debt-to-EBITDA

Genix Pharmaceuticals (TSXV:GENX) Debt-to-EBITDA : -4.11 (As of Jan. 2024)


View and export this data going back to 1999. Start your Free Trial

What is Genix Pharmaceuticals Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genix Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.58 Mil. Genix Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.00 Mil. Genix Pharmaceuticals's annualized EBITDA for the quarter that ended in Jan. 2024 was C$-0.14 Mil. Genix Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 was -4.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genix Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:

TSXV:GENX' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.37   Med: -0.13   Max: -0.04
Current: -0.15

During the past 13 years, the highest Debt-to-EBITDA Ratio of Genix Pharmaceuticals was -0.04. The lowest was -0.37. And the median was -0.13.

TSXV:GENX's Debt-to-EBITDA is ranked worse than
100% of 657 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs TSXV:GENX: -0.15

Genix Pharmaceuticals Debt-to-EBITDA Historical Data

The historical data trend for Genix Pharmaceuticals's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genix Pharmaceuticals Debt-to-EBITDA Chart

Genix Pharmaceuticals Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.04 -0.04 -0.37 -0.14

Genix Pharmaceuticals Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.03 -1.12 -5.85 -0.04 -4.11

Competitive Comparison of Genix Pharmaceuticals's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Genix Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genix Pharmaceuticals's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genix Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genix Pharmaceuticals's Debt-to-EBITDA falls into.



Genix Pharmaceuticals Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genix Pharmaceuticals's Debt-to-EBITDA for the fiscal year that ended in Oct. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.512 + 0) / -3.797
=-0.13

Genix Pharmaceuticals's annualized Debt-to-EBITDA for the quarter that ended in Jan. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.575 + 0) / -0.14
=-4.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jan. 2024) EBITDA data.


Genix Pharmaceuticals  (TSXV:GENX) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genix Pharmaceuticals Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genix Pharmaceuticals's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genix Pharmaceuticals (TSXV:GENX) Business Description

Traded in Other Exchanges
Address
1055 West Hastings Street, Suite 300, Vancouver, BC, CAN, V6E 1J8
Genix Pharmaceuticals Corp is a Canadian life sciences company. It operates as a formulator, manufacturer, licensor, and marketer of life sciences related products with a focus on nutraceuticals and pharmaceuticals. Some of its products are Renochlor, Sucanon, and Flu-X. The company primarily operates in Canada.
Executives
Sina Pirooz Director

Genix Pharmaceuticals (TSXV:GENX) Headlines

No Headlines